Skip to main content
Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc. — Investor Relations & Filings

Ticker · CLRB ISIN · US15117F8077 LEI · 5493000NFZCRG7BYQV93 US Manufacturing
Open in API
Filings indexed 1,033 across all filing types
Latest filing 2013-08-02 Capital/Financing Update
Country US United States of America
Listing US CLRB

About Cellectar Biosciences, Inc.

https://www.cellectar.com/

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted cancer treatments. The company's core technology is a proprietary Phospholipid Drug Conjugate (PDC) platform that selectively delivers therapeutic payloads, such as radioisotopes and cytotoxins, to cancer cells by targeting lipid rafts in their plasma membranes. This approach is designed to maximize antitumor activity while minimizing off-target effects on healthy tissue. Cellectar's lead product candidate is iopofosine I 131, a first-in-class PDC that delivers the radioisotope iodine-131. It is being developed for the treatment of hematologic malignancies and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Waldenstrom's Macroglobulinemia.

Recent filings

Filing Released Lang Actions
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 95% confidence The document is a 'Prospectus Supplement' filed pursuant to Rule 424(b)(3), which is a regulatory filing related to securities offerings. It details the sale of shares and warrants, leadership transitions, and compensatory arrangements for officers. The document is not a full financial report but rather an update on capital raising and related corporate matters. The presence of terms like 'Prospectus Supplement', 'Rule 424(b)(3)', and detailed share issuance information indicates this is a Capital/Financing Update. The document length is under 5,000 characters, but it contains substantive information about financing activities, not just an announcement of a report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2013-08-02 English
PROSPECTUS SUPPLEMENT
Regulatory Filings Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(3), which is a regulatory filing related to securities offerings. It includes information about a leadership transition and compensatory arrangements for officers, but the primary nature of the document is a supplement to a prospectus concerning the resale of shares. It is not a full financial report, earnings release, or management discussion. The document length is under 5,000 characters and it serves as a formal regulatory disclosure related to securities offerings. Therefore, it fits best under Regulatory Filings (RNS).
2013-08-02 English
CURRENT REPORT
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content focuses on changes in senior management, including the CEO stepping down, amendments to employment agreements, retention agreements for other executives, and new appointments. There are no financial statements or detailed financial data presented. The primary subject is management changes and related compensatory arrangements. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 5397 characters, which is sufficient to contain substantive information, not just a brief announcement or certification. Hence, the classification is MANG with high confidence.
2013-07-31 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 23, 2013, by Novelos Therapeutics, Inc. The key content is an Item 7.01 Regulation FD Disclosure, which states that a slide presentation dated May 23, 2013, providing an overview of products, is furnished as Exhibit 99.1 and incorporated by reference. The document itself is short (2527 characters) and primarily serves to announce the availability of a slide presentation rather than containing detailed financial data or a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the slide presentation) rather than the report itself. The slide presentation is investor-focused and provides an overview of products, which aligns with the definition of an Investor Presentation (IP). Therefore, the filing type is Investor Presentation (IP) with high confidence.
2013-05-24 English
FORM 424B3
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q quarterly report filed with the SEC for the quarter ended March 31, 2013. It contains detailed financial statements including balance sheets, statements of operations, cash flows, and notes to the financial statements. The presence of comprehensive financial data and management discussion confirms it is a substantive quarterly financial report, not merely an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2013-05-16 English
FORM 424B3
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q quarterly report filed with the SEC for the quarter ended March 31, 2013. It contains detailed financial statements including balance sheets, statements of operations, cash flows, and notes to the financial statements. The presence of actual financial data and management discussion confirms it is a comprehensive quarterly report rather than an announcement or certification. The document length is substantial (15,000 characters), indicating it is the report itself, not just a notice of filing. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2013-05-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.